📊 GUTS Key Takeaways
Is Fractyl Health, Inc.. (GUTS) a Good Investment?
Fractyl Health shows fundamental distress with zero revenue despite operating as a surgical instruments company, indicating failure to commercialize products or complete loss of revenue-generating capability. The company is burning $23M annually in free cash flow while operating at a $20.8M loss, making the current positive net income ($9.2M) appear driven by one-time gains rather than sustainable operations.
Fractyl Health is pre-revenue with very large operating and net losses, yielding extremely negative ROA/ROE and no visibility into unit economics. Liquidity is currently solid with substantial cash and no debt, but the burn rate implies roughly a year of runway and a high likelihood of additional capital needs. Until there is clear progress toward commercialization and operating leverage, the fundamental profile remains weak.
Why Buy Fractyl Health, Inc.. Stock? GUTS Key Strengths
- Strong cash position of $63.2M provides near-term runway
- Fortress balance sheet with zero long-term debt and 4.28x current ratio
- Positive stockholders' equity of $21.4M
- Strong liquidity (current ratio ~4.8x; $81.5M cash)
- Debt-free balance sheet reducing insolvency risk
- Low capex intensity provides expense flexibility
GUTS Stock Risks: Fractyl Health, Inc.. Investment Risks
- Complete revenue collapse: $0.00 in revenue (-100% YoY) indicates product commercialization failure or operational cessation
- Unsustainable cash burn: -$23.0M free cash flow annually provides only ~2.7 years of runway at current rates
- Operating losses of -$20.8M with positive net income suggests non-operating gains masking fundamental business failure
- Zero insider activity in 90 days suggests management loss of confidence
- Medical device sector requires revenue generation; zero revenue is terminal
- Pre-revenue status with no demonstrated commercial traction
- High cash burn likely necessitating dilutive financing
- Very small equity base and deeply negative ROA/ROE
Key Metrics to Watch
- Quarterly revenue and path to commercialization
- Operating cash flow trend and burn rate acceleration/deceleration
- Cash and equivalents balance and runway calculation
- Operating loss magnitude and whether it stabilizes
- Quarterly operating cash flow (cash burn) and runway
- Quarterly revenue and gross margin upon launch
Fractyl Health, Inc.. (GUTS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.28x current ratio provides a solid financial cushion.
GUTS Profit Margin, ROE & Profitability Analysis
GUTS vs Healthcare Sector: How Fractyl Health, Inc.. Compares
How Fractyl Health, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Fractyl Health, Inc.. Stock Overvalued? GUTS Valuation Analysis 2026
Based on fundamental analysis, Fractyl Health, Inc.. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Fractyl Health, Inc.. Balance Sheet: GUTS Debt, Cash & Liquidity
GUTS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Fractyl Health, Inc..'s revenue has declined by 23% over the 5-year period, indicating business contraction. The most recent EPS of $-1.62 indicates the company is currently unprofitable.
GUTS Revenue Growth, EPS Growth & YoY Performance
GUTS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $14.0K | -$3.3M | $-0.48 |
| Q2 2025 | $43.0K | -$3.3M | $-0.36 |
| Q1 2025 | $33.0K | -$3.3M | $-0.17 |
| Q3 2024 | $14.0K | -$3.3M | $-0.48 |
| Q2 2024 | $43.0K | -$3.3M | $-0.36 |
| Q1 2024 | $5.0K | -$3.3M | $-0.17 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Fractyl Health, Inc.. Dividends, Buybacks & Capital Allocation
GUTS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Fractyl Health, Inc.. (CIK: 0001572616)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GUTS
What is the AI rating for GUTS?
Fractyl Health, Inc.. (GUTS) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GUTS's key strengths?
Claude: Strong cash position of $63.2M provides near-term runway. Fortress balance sheet with zero long-term debt and 4.28x current ratio. ChatGPT: Strong liquidity (current ratio ~4.8x; $81.5M cash). Debt-free balance sheet reducing insolvency risk.
What are the risks of investing in GUTS?
Claude: Complete revenue collapse: $0.00 in revenue (-100% YoY) indicates product commercialization failure or operational cessation. Unsustainable cash burn: -$23.0M free cash flow annually provides only ~2.7 years of runway at current rates. ChatGPT: Pre-revenue status with no demonstrated commercial traction. High cash burn likely necessitating dilutive financing.
What is GUTS's revenue and growth?
Fractyl Health, Inc.. reported revenue of $0.0.
Does GUTS pay dividends?
Fractyl Health, Inc.. does not currently pay dividends.
Where can I find GUTS SEC filings?
Official SEC filings for Fractyl Health, Inc.. (CIK: 0001572616) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GUTS's EPS?
Fractyl Health, Inc.. has a diluted EPS of $0.06.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GUTS a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Fractyl Health, Inc.. has a SELL rating with 84% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GUTS stock overvalued or undervalued?
Valuation metrics for GUTS: ROE of 43.1% (sector avg: 15%), net margin of N/A (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy GUTS stock in 2026?
Our dual AI analysis gives Fractyl Health, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GUTS's free cash flow?
Fractyl Health, Inc..'s operating cash flow is $-22.5M, with capital expenditures of $557.0K.
How does GUTS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE 43.1% (avg: 15%), current ratio 4.28 (avg: 2).
Why is GUTS's return on equity (ROE) so high?
Fractyl Health, Inc.. has a return on equity of 43.1%, significantly above the Healthcare sector average of 15%. A high ROE indicates the company is efficient at generating profits from shareholder equity.